

***FDA/PQRI Workshop on the Regulatory  
Framework for Distributed and Point of  
Care Pharmaceutical Manufacturing***  
***An Opportunity for DM/POC Stakeholder Engagement***



## Organizers

- ❖ **Joanne Chia**, FDA CDER
- ❖ **Tom O'Connor**, FDA CDER
- ❖ **Nathan Davis**, FDA CDER
- ❖ **Adam Fisher**, FDA CDER
- ❖ **Elizabeth Friedman**, FDA CDER
- ❖ **Dede Godstrey**, PQRI Secretariat
- ❖ **Doug Kiehl**, Eli Lilly and Company
- ❖ **Jennifer Maguire**, FDA CDER
- ❖ **Riley Myers**, FDA CDER
- ❖ **Manuel Osorio**, FDA CBER
- ❖ **Diane Paskiet**, West Pharmaceutical Services
- ❖ **Jean Poulos**, Rochem International
- ❖ **Bhagwant Rege**, FDA CDER
- ❖ **Anna Scarbro**, FDA CDER
- ❖ **David Schoneker**, Black Diamond Regulatory Consulting, LLC, IPEC Americas
- ❖ **Pahala Simamora**, FDA CDER
- ❖ **Cat Vicente**, Johnson & Johnson
- ❖ **Glenn Wright**, PDA
- ❖ **Carolyn Yong**, FDA CBER
- ❖ **Maotang Zhou**, FDA CDER

## Speakers and Panelists

- ❖ **Ashley Boam**, FDA CDER
- ❖ **Celeste Frankenfeld Lamm**, Merck & Co., Inc.
- ❖ **Alvaro Goyanes**, FabRx and UCL School of Pharmacy
- ❖ **Michael Kopcha**, FDA CDER
- ❖ **John Lewin**, On Demand Pharmaceuticals, Inc.
- ❖ **J. Christopher Love**, MIT and Sunflower Therapeutics
- ❖ **Riley Myers**, FDA CDER
- ❖ **Thomas O'Connor**, FDA CDER
- ❖ **Richard McFarland**, Advanced Regenerative Manufacturing Institute
- ❖ **Christine Moore**, Organon
- ❖ **Steven Oh**, FDA CBER
- ❖ **Fred Parietti**, Multiply Labs
- ❖ **Dennis Powers**, G-Con
- ❖ **Laura Ricles**, FDA CBER
- ❖ **Thomas Roper**, Virginia Commonwealth University
- ❖ **Laura Sands**, Lonza
- ❖ **Rakhi Shah**, FDA CDER
- ❖ **Paul Smolenski**, DEKA Research and Development
- ❖ **Joel Welch**, FDA CDER
- ❖ **Carolyn Yong**, FDA CBER

Thank you for your participation!

If you have additional feedback, please submit comments on the DM/POC Discussion Paper under docket number FDA-2022-N-2316 by December 13<sup>th</sup>, 2022